{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:23:12Z","timestamp":1745245392248},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.3816\/clm.2006.n.036","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:10:46Z","timestamp":1221081046000},"page":"30-32","source":"Crossref","is-referenced-by-count":2,"title":["Diagnosis and Management of Lymphoma"],"prefix":"10.3816","volume":"7","author":[{"given":"Brian L.","family":"Abbott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib1","first-page":"424s","article-title":"Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts)","volume":"24","author":"Foussard","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.036_bib2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib3","first-page":"429s","article-title":"A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma (NHL)","volume":"24","author":"Williams","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib4","first-page":"441s","article-title":"Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed\/refractory indolent non-Hodgkin's lymphoma (NHL)","volume":"24","author":"Santoro","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib5","first-page":"684s","article-title":"Ten year retrospective analysis of BOP (bleomycin, vincristine, predinisone) \u2013 a novel non-myelosuppressive chemotherapy regimen for treatment of non-Hodgkin's lymphoma","volume":"24","author":"Chan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib6","first-page":"124s","article-title":"A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors","volume":"24","author":"Tolcher","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib7","first-page":"437s","article-title":"Rituximab, gemcitabine and oxaliplatin (R-GEMOX): an effective regimen for relapsed and refractory B-cell lymphoma","volume":"24","author":"El Gnaoui","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib8","first-page":"681s","article-title":"A dose dense low toxicity salvage regimen for histologically aggressive non-Hodgkin's lymphoma (NHL): gemcitabine, rituximab, oxaliplatin combination (GROC) plus pegfilgrastim","volume":"24","author":"Cabanillas","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib9","first-page":"682s","article-title":"Gemcitabine, ifosfamide, oxaliplatin and rituximab (RGIFOX), a new effective cytoreductive\/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study","volume":"24","author":"Corazzelli","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib10","first-page":"685s","article-title":"Vinorelbine-based salvage therapy for patients with aggressive leukemias and non-Hodgkin's lymphomas","volume":"24","author":"Morar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib11","first-page":"430s","article-title":"Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)","volume":"24","author":"Flinn","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib12","first-page":"602s","article-title":"Tandem HDchemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: results of a phase II study of the German RAIT Study Group","volume":"24","author":"Hohloch","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib13","first-page":"424s","article-title":"Mantle cell lymphoma (MCL): induction therapy with HyperCVAD\/high-dose methotrexate and cytarabine (M-C) (+\/\u2212 rituximab) improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib14","first-page":"680s","article-title":"Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189)","volume":"24","author":"Inwards","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib15","first-page":"436s","article-title":"Sequential radioimmunotherapy with tositumomab\/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions","volume":"24","author":"Zelenetz","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib16","first-page":"422s","article-title":"Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1499)","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib17","first-page":"425s","article-title":"Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): results of the PINNACLE study","volume":"24","author":"Goy","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib18","first-page":"430s","article-title":"Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"24","author":"Ansell","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib19","first-page":"422s","article-title":"Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): results of a phase IIb trial","volume":"24","author":"Olsen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib20","first-page":"136s","article-title":"International multicenter phase II study of the HDAC inhibitor (HDACI) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): interim report","volume":"24","author":"Whittaker","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib21","first-page":"422s","article-title":"LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy","volume":"24","author":"Prince","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib22","first-page":"432s","article-title":"Allogeneic hematopoietic stem cell transplantation for cutaneous T-cell lymphoma (CTCL)","volume":"24","author":"Hosing","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib23","first-page":"431s","article-title":"CHOP\/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL","volume":"24","author":"Trumper","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib24","first-page":"445s","article-title":"Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: preliminary results","volume":"24","author":"Porcu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.036_bib25","first-page":"446s","article-title":"A phase II study of HCVIDDOXIL alternated with methotrexatecytarabine in patients with newly diagnosed T-cell lymphoma","volume":"24","author":"Pro","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T17:58:41Z","timestamp":1545760721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1557919011703043"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.n.036","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}